Will Gilead Sciences Make a Fortune Off Its Coronavirus Drug?

Will Gilead Sciences Make a Fortune Off Its Coronavirus Drug?

Source: 
Motley Fool
snippet: 

As the coronavirus outbreak continues to spread around the world, only a couple of companies have successfully brought treatments to clinical trials so far. One of them is Gilead Sciences (NASDAQ: GILD), whose former Ebola drug candidate, remdesivir, appears to be an effective way to treat COVID-19 symptoms.